A combination of two pills proved extremely effective in treating hepatitis C in a small trial, raising hopes among researchers that the disease will be curable without an injected drug that has debilitating side effects. But the combination might not find its way to the market because one pill is owned by Gilead Sciences and the other by Bristol-Myers Squibb.
Collaboration on hepatitis drugs lags
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.